Has Roshana Nazari received payments from drug or device companies?

Yes. Drug and device makers reported $3,541 in general payments to Roshana Nazari across 130 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roshana Nazari did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roshana Nazari come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roshana Nazari

Psychiatric/Mental Health · Redlands, CANPI 1104647205

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations.

$3,541in general payments, 2019–2025

Across 130 payments — averaging $27.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurocrine Biosciences, Inc.$734
Teva Pharmaceuticals USA, Inc.$620
Johnson & Johnson$547
Otsuka America Pharmaceutical, Inc.$408
Alkermes, Inc.$347
Lundbeck LLC$308
plus $578 from 10 others

What the payments were for

Food & beverage$3,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurocrine Biosciences, Inc.	30	$734
Teva Pharmaceuticals USA, Inc.	21	$620
Johnson & Johnson	13	$547
Otsuka America Pharmaceutical, Inc.	18	$408
Alkermes, Inc.	7	$347
Lundbeck LLC	14	$308
Luye Pharma (USA) Ltd.	3	$159
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	8	$153
Collegium Pharmaceutical, Inc.	5	$76
E.r. Squibb & Sons, L.L.C.	3	$63
Noven Therapeutics, LLC	2	$39
Axsome Therapeutics, Inc.	1	$24
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$19
Corium, LLC	2	$18
Takeda Pharmaceuticals U.S.A., Inc.	1	$14
Almatica Pharma LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,541 in reported general payments places this provider in the 85th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California →

Other psychiatric/mental health in Redlands

Liberty MaciasRedlands$288K
John AdenijiRedlands$29K
Magnus IhemeduRedlands$15K
Jogendra SinghRedlands$13K
Akta PatelRedlands$11K
Linda JacksonRedlands$11K
Carey MartinMillbrae$745K
Joshua BurgettSacramento$239K
Jovita Ezirim-SalamialofojeLos Angeles$162K
Angie-Kolleen TanThousand Oaks$159K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →